McKesson (NYSE:MCK) Issues Quarterly Earnings Results

McKesson (NYSE:MCK) announced its earnings results on Thursday, October 25th. The company reported $3.60 EPS for the quarter, topping the Zacks’ consensus estimate of $3.28 by $0.32, Fidelity Earnings reports. The firm had revenue of $53.08 billion during the quarter, compared to analysts’ expectations of $53.56 billion. McKesson had a return on equity of 26.55% and a net margin of 0.06%. McKesson updated its FY 2019 guidance to $13.20-13.80 EPS.

NYSE MCK traded down $1.76 on Friday, reaching $130.81. 805,179 shares of the stock traded hands, compared to its average volume of 1,715,922. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The firm has a market cap of $25.93 billion, a PE ratio of 10.37, a price-to-earnings-growth ratio of 1.51 and a beta of 1.05. McKesson has a 12 month low of $117.19 and a 12 month high of $178.86.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Friday, November 30th. McKesson’s dividend payout ratio (DPR) is presently 12.36%.

In other McKesson news, Director N Anthony Coles sold 1,350 shares of McKesson stock in a transaction on Friday, August 31st. The stock was sold at an average price of $128.69, for a total transaction of $173,731.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.87% of the company’s stock.

A number of research firms recently issued reports on MCK. Jefferies Financial Group restated a “buy” rating and set a $160.00 price objective on shares of McKesson in a report on Friday, July 27th. Robert W. Baird cut McKesson from an “outperform” rating to a “neutral” rating in a report on Friday, July 20th. Citigroup dropped their price objective on McKesson from $160.00 to $2.86 and set a “buy” rating for the company in a report on Friday, July 20th. Mizuho restated a “hold” rating and set a $133.00 price objective on shares of McKesson in a report on Sunday, August 12th. Finally, ValuEngine upgraded McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, October 29th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $150.26.

COPYRIGHT VIOLATION WARNING: This story was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Earnings History for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.

Leave a Reply